Cł

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C. 20549	
---------------	------------	--

Check this box if no longer subject						
to Section 16. Form 4 or Form 5						
obligations may continue. See						
Instruction 1(b).						

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* CROCKER GARY L				MI	2. Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [MACK]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(Fii	rst) (M	ліddle)											X	Office belov	er (give titl v)	е	Othe belo	r (specify w)	
C/O MERRIMACK PHARMACEUTICALS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 03/16/2021									See Remarks							
ONE BROADWAY 14TH FLOOR																				
(Street) CAMBRIDGE MA 02142				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(City) (State) (Zip)														Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			ear) E	2A. Deeme Execution if any (Month/Day		Ti	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			d (A) or r. 3, 4 and	Benefic		es ally Following	Form (D) or Indire	ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							С	Code		Am	ount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(111301.4)	
Common Stock		03/16/202	1				P		5,000		A	\$6.791	2 ⁽¹⁾	20,104		1 1		See Footnote ⁽²⁾		
		Tal	ole II - Derivat (e.g., pı												Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		ansaction of ode (Instr. Derivativ			Exp	piratior	kercisable and n Date ay/Year)		Amo Secu Unde Deri	tle and bunt of urities erlying vative urity (Instr d 4)	Der Sed (Ins	Price of erivative ecurity istr. 5)	9. Numbe derivativ Securitie Beneficia Owned Following Reported Transact (Instr. 4)	e s ally g	10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownershi ct (Instr. 4)	
				Code	v	(A)	(D)	Dat Exe	te ercisab	ole	Expiration Date	Title	Amount or Number of Shares	r						

Explanation of Responses:

Remarks:

Chairman, President, and Treasurer

/s/ Gary L. Crocker 03/17/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$6.67 to \$6.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

^{2.} Shares held by Crocker Family Investments, LLC, over which Reporting Person is the Managing Member.